Delving into the Latest Updates on Articaine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Articaine, Articaine hydrochloride (JAN/USP), 40-045

+ [7]

Target

SCNA

Action

blockers, modulators

Mechanism

SCNA blockers(Sodium voltage-gated channel alpha subunits blockers), Central nervous system modulators

Therapeutic Areas

Other Diseases

Active Indication

Anesthesia

Inactive Indication-

Originator Organization

North American Genomics LLC

Active Organization-

Inactive Organization

Thea Pharma Inc.American Genomics, LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (15 Aug 2025),

Anesthesia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC13H21ClN2O3S

InChIKeyGDWDBGSWGNEMGJ-UHFFFAOYSA-N

CAS Registry23964-57-0

This concise, evidence-based review explores pharmacological principles of local anesthetics describing key aspects of structure-activity relationship, providing context for agent selection. Additional considerations include dosing strategy, adjunctive medications, potential risks, toxicity mitigation, and operationalization of regional anesthesia in the ED.

DISCUSSION:

Regional anesthesia is used with increased frequency in the ED. Pharmacologic properties of commonly used local anesthetics and adjunctive agents determine their advantages and limitations as well as place in therapy. There are a variety of anesthetic agents, including amides (e.g., lidocaine, bupivacaine, ropivacaine, levobupivacaine) and esters (e.g., articaine, chloroprocaine) with differences in onset, duration, and toxicity profiles that influence agent selection in ED patient populations. Adjuncts such as epinephrine, dexamethasone, and alpha-2 agonists may extend nerve block duration or improve analgesia but introduce safety and operational considerations. Recognition of local anesthetic systemic toxicity (LAST) remains central to safe practice, underscoring the importance of weight-based dosing, ultrasound guidance, monitoring, and immediate access to lipid emulsion therapy. Systems-based approaches such as order sets, pharmacist involvement, and structured training support consistent and safe application of regional anesthesia in the ED setting.

CONCLUSIONS:

Safe integration of regional anesthesia in the ED requires pharmacologic literacy, standardized systems, and multidisciplinary support to optimize analgesia while minimizing risk.

01 Apr 2026·Journal of Pharmacy and Bioallied Sciences

Efficacy of Different Local Anesthetics for Pain Management in Surgical Removal of Palatally Placed Impacted Maxillary Canines: A Comparative Study

Article

Author: Kilari, Dharani Chowdary ; Alqahtani, Ali Fahed ; Tiwari, Rahul ; Malhotra, Aayush ; Ahmed, Tanveer ; Das, Nirman ; Kota, Mohammad Zahir ; Prashant, M. C.

Objective::

To compare the efficacy of different local anesthetics in managing pain during the surgical removal of palatally placed impacted maxillary canines.

Materials and Methods::

A randomized controlled study was conducted on 90 patients requiring surgical removal of palatally impacted maxillary canines. Patients were divided into three groups, each receiving a different local anesthetic: 2% lidocaine with epinephrine (Group A), 4% articaine with epinephrine (Group B), and 0.5% bupivacaine with epinephrine (Group C). Pain levels were assessed intraoperatively and postoperatively using the Visual Analog Scale (VAS).

Results::

Articaine demonstrated superior intraoperative pain control compared to lidocaine and bupivacaine (VAS score: 1.5 ± 0.6 vs. 3.2 ± 0.8 and 2.8 ± 0.7, respectively, P < 0.05). Postoperative pain relief was significantly prolonged in the bupivacaine group (VAS score at 6 hours: 2.1 ± 0.9 vs. 4.5 ± 1.0 for lidocaine and 3.8 ± 0.9 for articaine, P < 0.05). No severe adverse effects were reported in any group.

Conclusion::

Articaine provides superior intraoperative pain control, while bupivacaine offers longer-lasting postoperative analgesia. The choice of anesthetic should depend on the clinical requirements of intraoperative versus postoperative pain management.

01 Mar 2026·MILITARY MEDICINE

Effects of Simulated Field Storage Conditions on Common Dental Medications

Article

Author: Vandewalle, Kraig S ; Ledesma, Logan G ; Rose, Meaghan A ; Zamora, Heather M ; McIntosh, Zachary S ; Hwang, Yoon Y

Abstract:

Introduction:

Military dental providers often operate in environments with extreme temperature gradients. The purpose of this study was to analyze the effect of simulated storage in extreme cold conditions on 8 medications—4 local anesthetics (2% Lidocaine with 1:100,000 epinephrine, 0.5% Marcaine with 1:200,000 epinephrine, 4% Articaine with 1:100,000 epinephrine, 3% Polocaine), 2 pain medications (Acetaminophen 325 mg, Ibuprofen 800 mg), and 2 antibiotics (Amoxicillin 500 mg, Azithromycin 500 mg), who are commonly used by the military for dental treatment.

Materials and Methods:

Medications were subjected to simulated freeze-thaw (FT) conditions (MIL-STD-810H), using an environmental chamber to expose any tendency for degradation. The medications were cycled through 13 hours at −10 °C and 11 hours at 4 °C for 28 days, to simulate springtime FT conditions experienced by Kyiv, Ukraine. Samples were analyzed at 0, 7, 14, 21, and 28 days under both environmental stress and room temperature (RT) conditions. Liquid chromatography—mass spectrometry (LC-MS) was completed with electrospray ionization interface and triple quadrupole mass analyzer. Each medication was used as an internal standard (IS) for the other and response factors determined for each. All drugs and their respective IS were measured in multiple reaction monitoring in electrospray positive ionization. Room temperature data from each time point were compared to the respective environmentally stressed drug data using T-tests adjusted via Bonferroni’s method (α = 0.01). Parametric first-order autoregressive moving-average repeated-measures analysis of variance using maximum likelihood was performed using the “MIXED” procedure in SAS v9.4 to determine if concentrations were affected by time and environmental stress (α = 0.05).

Results:

Lidocaine, Polocaine, Acetaminophen, and Azithromycin concentrations were affected by time and environmental stressing. All other medication concentrations were affected by time but not by environmental stressing.

Conclusions:

Utilization and/or storage of commonly used local anesthetics, antibiotics, and pain medications in these climate conditions may experience concentration changes who may affect their efficacy in treating dental-related conditions.

1

News (Medical) associated with Articaine Hydrochloride

02 Jan 2026

·www.einpresswire.com

July - September 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

ADZYNMA (ADAMTS13, recombinant-krhn) Neutralizing antibodies with fatal outcome FDA is evaluating the need for regulatory action. FDA Safety Communication was issued on November 21, 2025: FDA Investigating Death Due to Neutralizing Antibodies to ADAMTS13 following Adzynma Treatment of Congenital Thrombotic Thrombocytopenic Purpura Asceniv (immune globulin intravenous, human-slra) Increased hypersensitivity reactions in patients receiving certain product lot FDA is evaluating the need for regulatory action. FDA Safety Communication was issued on October 28, 2025: Immune Globulin Intravenous (IGIV) and/or Immune Globulin Subcutaneous (IGSC) Lots with Increased Reports of Allergic/Hypersensitivity Reactions Benlysta (belimumab) injection Severe cutaneous adverse reactions FDA is evaluating the need for regulatory action. Braftovi (encorafenib) capsules Tafinlar (dabrafenib) capsules; tablets Zelboraf (vemurafenib) tablet Sarcoidosis FDA is evaluating the need for regulatory action. Cabometyx (cabozantinib) tablets Cometriq (cabozantinib) capsules Lenvima (lenvatinib) capsules Thrombotic microangiopathy FDA is evaluating the need for regulatory action. Cotellic (cobimetinib) tablets Mekinist (trametinib) tablets; oral solution Mektovi (binimetinib) tablets Sarcoidosis FDA is evaluating the need for regulatory action. ELEVIDYS (delandistrogene moxeparvovec-rokl) Mesenteric vein thrombosis following product-related acute liver injury The "Warnings and Precautions" and "Adverse Reactions - Postmarketing Experience" sections of the labeling for Elevidys were updated in November 2025 to include life-threatening mesenteric vein thrombosis. FDA Safety Communication was issued on November 14, 2025: FDA Takes Action on New Boxed Warning for Acute Serious Liver Injury and Acute Liver Failure Following Treatment with Elevidys and Revised Indication that is Limited to Ambulatory Duchenne Muscular Dystrophy Patients Firmagon (degarelix for injection) Myfembree (relugolix, estradiol, and norethindrone acetate) tablets Orgovyx (relugolix) tablets Drug interaction FDA is evaluating the need for regulatory action. Ifex (ifosfamide) injection Pregnancy, puerperium and perinatal conditions FDA is evaluating the need for regulatory action. Ogsiveo (nirogacestat) tablets Visual impairment FDA is evaluating the need for regulatory action. Orgovyx (relugolix) tablets Hypertension FDA is evaluating the need for regulatory action. Rezzayo (rezafungin for injection) Hypersensitivity The "Warnings and Precautions", "Adverse Reactions" and "Patient Counseling Information" sections of the labeling were updated in December 2025 to include information about hypersensitivity reactions, including anaphylaxis. Rezzayo labeling Septocaine (articaine hydrochloride and epinephrine injection) Mepivacaine hydrochloride injection (a particular generic product) Wrong drug administered FDA is evaluating the need for regulatory action. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalBiosimilar

100 Deals associated with Articaine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02991	Articaine Hydrochloride	N01BB08	DB09009

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	United States	Thea Pharma Inc.	15 Aug 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05443009 (Pubmed \| J Am Dent Assoc)	Phase 3	Pain	76	4% articaine	asabubzssd(rkqsyoyazm) = rlzfshipmx nndkdndaqt (joedrpcwtj, 3.41)	Negative	01 Nov 2025
				2% lidocaine (buccal and palatal infiltration)	asabubzssd(rkqsyoyazm) = volvikjvjx nndkdndaqt (joedrpcwtj, 2.71)
FDA_CDER Manual	Phase 1	-	240	ARTICAINE	sgbgcypoja(wqmcqjjmlz) = The treatment effect (difference from placebo) was 65% in both studies. pkwsvgqsbq (lqtnuieqkz )	Positive	15 Aug 2025
				placebo
NCT06047366 (CTgov)	Phase 4	Pulpitis	40	Articaine w/ epi+Mepivacaine plain+Sodium bicarbonate+Lidocaine w/ epi (Buffered)	ncswcmebzb(bgtctmnmyp) = sulawebhby wsvypabqca (ywwxgodace, lpgsytesdw - dhzhoxazpu) View more	-	13 May 2025
				Articaine w/ epi+Mepivacaine plain+Lidocaine w/ epi (Unbuffered)	ncswcmebzb(bgtctmnmyp) = kxgagzgcyn wsvypabqca (ywwxgodace, mradylpkxo - diovdqdnoc) View more
NCT04829344 (CTgov)	Phase 3	Anesthesia	120	AG-920 (AG-920)	anotdueuvn(wdmczbxhbj) = hjjanqlyif fjidbkhzwf (ydteoaoqxc, 0.61) View more	-	10 Oct 2024
				Placebo (Placebo)	anotdueuvn(wdmczbxhbj) = jqopxpsrve fjidbkhzwf (ydteoaoqxc, 1.67) View more
NCT05501860 (CTgov)	Phase 3	Anesthesia	249	AG-920 (AG-920)	jhqagnyvla = kwyzkggdjo iwsczzlsep (smcsvozwlg, ahvjypmkcd - xibbemnpkr) View more	-	09 Oct 2024
				Placebo (Placebo)	jhqagnyvla = mpitemaqeq iwsczzlsep (smcsvozwlg, gcmerzpnqn - zrwuyfsaaq) View more
NCT05325853 (Phase 3, CTgov)	Phase 3	Anesthesia	61	AG-920 (AG-920)	xogbfcmpnz = onlcezzrxv vojcxzwaie (bqztfhvfxs, ywbbzbwrof - vlqkwmuxuv) View more	-	25 Oct 2023
				Proparacaine Ophthalmic (Proparacaine)	xogbfcmpnz = votiruqjtm vojcxzwaie (bqztfhvfxs, zalgomblza - yjelaxzmyc) View more
NCT04513652 (CTgov)	Phase 3	Anesthesia	120	AG-920 (AG-920)	rxbaebmjms = ckjtyrfmke dptqsrcclz (cyvwfptrgy, egfsrnfnih - wkyvvxfkpu) View more	-	28 Sep 2022
				Placebo (Placebo)	rxbaebmjms = jciwbzwdfz dptqsrcclz (cyvwfptrgy, pponsfsptp - grhectrfme) View more
Phase 3 (ARVO2022)	Phase 3	-	120	AG-920	zczxxabjsk(xxkfybwqwg) = 9% vs 10% fvnjggoiwr (nxiazcrlex ) View more	Positive	01 May 2022
				Placebo
NCT01862614 (Buffered Articaine, CTgov)	Phase 4	Anesthesia	80	articaine (Articaine)	fsrigjjlov = ecxzmlqycz lauonweuqz (dsisqdxhrn, rhicbafykz - qehacpdewc) View more	-	02 Dec 2020
				articaine (Buffered Articaine)	fsrigjjlov = uzromdczha lauonweuqz (dsisqdxhrn, loiroyjhaq - mwyhahyjpc) View more
NCT02457325 (CTgov)	Phase 4	Blood Loss, Surgical \| Drug-Related Side Effects and Adverse Reactions	50	articaíne (Surgery With 2%Articaine)	snhbqheupn(gjslxjpdkq) = smhpastcoo mvlydrukci (aqavuzzbkb, 0.6) View more	-	24 Nov 2020
				articaíne (Surgery With 4%Articaine)	snhbqheupn(gjslxjpdkq) = jscncuisvh mvlydrukci (aqavuzzbkb, 0.6) View more